Microbiome diversity in carriers of fluoroquinolone resistant
Anti-bacterial agents
Escherichia coli
Infection
Microbiota
Prostate
Journal
Investigative and clinical urology
ISSN: 2466-054X
Titre abrégé: Investig Clin Urol
Pays: Korea (South)
ID NLM: 101674989
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
04
11
2018
accepted:
03
02
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
10
1
2020
Statut:
ppublish
Résumé
Fluoroquinolone-resistant (FQR) We perform an observational study to investigate the microbiome differences in men with and without FQR organisms found on rectal culture. A rectal swab with two culturettes was performed on men before an upcoming prostate biopsy procedure as standard of care to perform "targeted prophylaxis." Detection of FQR was performed by the standard microbiology lab inoculates the swab onto MacConkey agar containing ciprofloxacin. The extra swab was sent for 16S rRNA amplicon sequencing (MiSeq paired-end) using the V1V2 primer. Alpha and beta-diversity analysis were performed using QIIME. We used PERMANOVA to evaluate the statistical significance of beta-diversity distances within and between groups of interest. We collected 116 rectal swab samples before biopsy for 16S rRNA amplicon sequencing. We identified 18 isolates (15.5%, 18/116) that were positive and had relative reduced diversity profiles (p<0.05). Enterobacteriaceae were significantly over-represented in the FQR subjects (adjusted p=0.03). Microbiome analysis determined that men colonized with FQR bacteria have less diverse bacterial communities (dysbiosis), higher levels of Enterobacteriaceae and reduced levels of
Identifiants
pubmed: 30838339
doi: 10.4111/icu.2019.60.2.75
pmc: PMC6397931
doi:
Substances chimiques
Fluoroquinolones
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-83Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI104681
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST: Resphera Biosciences was paid to perform the microbiome analysis, and Dr. White is the owner of the company.
Références
J Urol. 2014 Dec;192(6):1673-8
pubmed: 24928266
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8922-6
pubmed: 9671780
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
PLoS One. 2013 Dec 31;8(12):e83823
pubmed: 24391833
Int J Mol Sci. 2018 Nov 22;19(12):
pubmed: 30469463
ILAR J. 2015;56(2):205-17
pubmed: 26323630
Nature. 2017 Jun 22;546(7659):528-532
pubmed: 28614296
PLoS Biol. 2012;10(8):e1001377
pubmed: 22904687
PLoS One. 2014 Jul 14;9(7):e101344
pubmed: 25020051
Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2081-5
pubmed: 7892228
Bioinformatics. 2010 Jan 15;26(2):266-7
pubmed: 19914921
Nature. 2011 May 12;473(7346):174-80
pubmed: 21508958
Clin Infect Dis. 2013 Jul;57(2):267-74
pubmed: 23532481
J Urol. 2012 Apr;187(4):1275-9
pubmed: 22341272
Nat Med. 2013 May;19(5):576-85
pubmed: 23563705
J Urol. 2011 Nov;186(5):1830-4
pubmed: 21944136
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
PLoS One. 2017 Jan 27;12(1):e0170742
pubmed: 28129384
Front Microbiol. 2013 Apr 17;4:87
pubmed: 23616784
Nature. 2012 Jun 13;486(7402):215-21
pubmed: 22699610
mBio. 2014 Jan 07;5(1):e00944-13
pubmed: 24399857
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
PLoS One. 2012;7(6):e39315
pubmed: 22720093
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
Clin Infect Dis. 2015 Apr 1;60(7):979-87
pubmed: 25516194
Int J Antimicrob Agents. 2014 Apr;43(4):301-9
pubmed: 24630305
Microbiome. 2018 Apr 20;6(1):73
pubmed: 29678198
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9827-32
pubmed: 8790416